Research on cancer drug therapy effect prediction for appropriate use of medical resources and control of medical expenses

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K07701
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Nagasaki University
• Principal Investigator: FUKUDA Minoru 長崎大学, 医歯薬学総合研究科(医学系), 客員研究員 (50388930)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 血管内皮増殖因子阻害薬 / 免疫チェックポイント阻害薬

Outline of Final Research Achievements

Ramucirumab/docetaxel therapy: 15 specimens collected, 7 analyzed. Median VEGF-D 310(119-457) mg/ml, median Tie2 188(129-327); median progression-free survival (low/high VEGF group) 85/105.5days, median progression-free survival (low/high Tie2 group) 85/105.5days. Progression-free survival was lower in the low VEGF and Tie 2 groups. Blood biomarkers (NY-ESO-1/XAGE1 antibody) were measured before treatment in 15 patients receiving immune checkpoint inhibitor therapy. 10 patients were negative and 5 were positive. Disease control rate 50%/60% in negative/positive group, median overall survival 168/589 days, negative cases less effective. The results seem to be predictive of a group of patients with poor efficacy.

Free Research Field

臨床腫瘍学

Academic Significance and Societal Importance of the Research Achievements

血管内皮増殖因子(VEGF)阻害薬は高額であるため、既治療非小細胞肺癌に対するラムシルマブとドセタキセル併用療法は1回に約43万円の治療を3週毎に繰り返す高額な治療であるが効果の乏しい場合がある。免疫チェックポイント阻害療法は多くの癌腫にその適応が拡大されておりニボルマブ単剤で1回に約40万円の治療を2週毎に繰り返す高額な治療であるが、効果の乏しい場合がある。血管内皮増殖因子阻害薬、免疫チェックポイント阻害薬における治療効果の低い患者群を予測することで適正な医療資源活用と医療費抑制に役立ち学術的意義や社会的意義は大きい。